160. 先天性魚鱗癬 Congenital ichthyosis Clinical trials / Disease details


臨床試験数 : 42 薬物数 : 71 - (DrugBank : 21) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 112

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04154293
(ClinicalTrials.gov)
December 3, 20191/11/2019A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital IchthyosisA Randomized, Parallel, Double-Blind, Vehicle Controlled Study to Evaluate the Safety and Efficacy of Two Concentrations of Topical TMB-001 for the Treatment of Congenital IchthyosisCongenital IchthyosisDrug: Isotretinoin;Other: VehicleTimber Pharmceuticals LLCNULLCompleted9 YearsN/AAll34Phase 2United States;Australia
2NCT03445650
(ClinicalTrials.gov)
July 18, 201814/2/2018RESET Trial - Part 1 (Followed by Reset Trial - Part 2) - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream (Reproxalap) in Subjects With Sjögren-Larsson Syndrome (SLS)Sjogren-Larsson SyndromeDrug: ADX-102 1% Topical Dermal Cream (reproxalap);Drug: Vehicle of ADX-102 Topical Dermal CreamAldeyra Therapeutics, Inc.NULLCompleted3 YearsN/AAll11Phase 3United States
3NCT02864082
(ClinicalTrials.gov)
March 8, 20173/8/2016A Safety and Tolerability Study of Topical PAT-001 in Congenital IchthyosisA Randomized, Bilateral Comparison, Vehicle-Controlled, Safety and Tolerability Study of Topical PAT-001 for the Treatment of Congenital IchthyosisCongenital IchthyosisDrug: PAT-001, 0.1%;Drug: PAT-001, 0.2%;Drug: VehiclePatagonia Pharmaceuticals, LLCNULLCompleted12 YearsN/AAll19Phase 2United States
4NCT02402309
(ClinicalTrials.gov)
March 201517/3/2015A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)Phase II Study of the Safety, Pharmacokinetics, and Exploratory Activity of Once Daily (QD) Topical Application of NS2 Cream to Treat Ichthyosis in Subjects With Sjögren-Larsson Syndrome (SLS)Sjögren-Larsson SyndromeDrug: Active topical NS2 1% dermatologic cream;Drug: Vehicle placebo 0.0% NS2 dermatologic creamAldeyra Therapeutics, Inc.NULLCompleted6 YearsN/AAll12Phase 2United States
5NCT01428297
(ClinicalTrials.gov)
May 201119/8/2011A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton SyndromeA First-In-human Study to Evaluate Safety and Tolerability of Topical BPR277 in Healthy Volunteers, and Proof of Concept (PoC) Studies to Evaluate the Safety, Tolerability, and Efficacy of Topical BPR277 in Patients With Atopic Dermatitis and Netherton SyndromeHealthy Volunteers;Atopic Dermatitis;Netherton SyndromeDrug: BPR277 ointment (controlled application);Drug: Placebo (Vehicle);Drug: BPR277 ointment;Drug: BPR277Novartis PharmaceuticalsNULLCompleted18 Years65 YearsAll12Phase 1United States;Netherlands;France;Germany